LLY Eli Lilly and Company
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
Company profile
Ticker
LLY
Exchange
Website
CEO
David A. Ricks
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
LILLY ELI & CO, LILLY ELI & CO ET AL
SEC CIK
Corporate docs
IRS number
350470950
LLY stock data
()
Calendar
31 Jul 20
23 Sep 20
31 Dec 20
News
Financial summary
| Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 8 Sep 20 | Melissa S Barnes | Common Stock | Sell | Dispose S | Yes | 151.01 | 5,000 | 755.05K | 23,580 |
| 1 Sep 20 | Michael B Mason | Common Stock | Payment of exercise | Dispose F | No | 148.39 | 2,735 | 405.85K | 18,544 |
| 1 Sep 20 | Michael B Mason | Common Stock | Option exercise | Aquire M | No | 0 | 6,244 | 0 | 21,279 |
| 1 Sep 20 | Michael B Mason | RSU Common Stock | Option exercise | Dispose M | No | 0 | 6,244 | 0 | 0 |
| 17 Aug 20 | Tai Jackson P | Common Stock | Grant | Aquire A | No | 151.53 | 13 | 1.97K | 58,301 |
| 17 Aug 20 | Fry Stephen F | Common Stock | Sell | Dispose S | Yes | 150.64 | 7,204 | 1.09M | 100,211 |
| 20 Jul 20 | Tai Jackson P | Common Stock | Grant | Aquire A | No | 167.04 | 12 | 2K | 58,288 |
Institutional ownership Q2 2020
76.6% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1708 |
| Opened positions | 168 |
| Closed positions | 108 |
| Increased positions | 570 |
| Reduced positions | 662 |
13F shares |
Current |
|---|---|
| Total value | 944.92B |
| Total shares | 732.44M |
| Total puts | 4.39M |
| Total calls | 3.83M |
| Total put/call ratio | 1.1 |
Largest owners |
Shares | Value |
|---|---|---|
| Lilly Endowment | 111.56M | $18.32B |
| Vanguard | 71.61M | $11.76B |
| BLK BlackRock | 62.83M | $10.32B |
| Primecap Management | 39.63M | $6.51B |
| STT State Street | 36.7M | $6.03B |
| FMR | 29.99M | $4.92B |
| Wellington Management | 26.99M | $4.43B |
| Capital International Investors | 21.18M | $3.48B |
| State Farm Mutual Automobile Insurance | 18.62M | $3.06B |
| JPM JPMorgan Chase & Co. | 15.94M | $2.62B |
Financial report summary
?Management Discussion
- Management’s discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Item 1 of Part I of this Quarterly Report on Form 10-Q. Certain statements in this Item 2 of Part I of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q and Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2019, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
Asian, axial, BePurchased, breast, cert, declared, description, dividend, Donald, Evox, Gemzar, hold, inclusion, Junshi, left, mandated, metastatic, mid, modestly, neurological, Neutralizing, nondeductible, ofPublicly, overturning, payable, resolved, Retevmo, science, Shanghai, SharesPurchased, stage, straight, Tauvid, Undisclosed, verification
Removed:
Adcirca, Breakthrough, Evaluation, expiring, hearing, largest, October, offering, prejudice, rapidly, Spain, standard, temporary
Financial reports
10-Q
2020 Q2
Quarterly report
31 Jul 20
10-Q
2020 Q1
Quarterly report
1 May 20
10-K
2019 FY
Annual report
19 Feb 20
10-Q
2019 Q3
Quarterly report
25 Oct 19
10-Q
2019 Q2
Quarterly report
2 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
10-K
2018 FY
Annual report
19 Feb 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
10-Q
2018 Q2
Quarterly report
25 Jul 18
10-Q
2018 Q1
Quarterly report
27 Apr 18
Current reports
8-K
Other Events
21 Aug 20
8-K
Lilly Reports Second-Quarter Financial Results, Raises EPS Guidance
30 Jul 20
8-K
Submission of Matters to a Vote of Security Holders
5 May 20
8-K
Other Events
28 Apr 20
8-K
Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance
23 Apr 20
8-K
Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition
30 Jan 20
8-K
Amendments to Articles of Incorporation or Bylaws
20 Dec 19
8-K
Lilly Announces 2020 Financial Guidance, Updates 2019 Guidance
17 Dec 19
8-K
Other Events
6 Nov 19
8-K
2018 FY
Other Events
24 Oct 19
Registration and prospectus
424B2
Prospectus for primary offering
21 Aug 20
FWP
Free writing prospectus
20 Aug 20
424B2
Prospectus for primary offering
20 Aug 20
424B5
Prospectus supplement for primary offering
27 Apr 20
FWP
Free writing prospectus
24 Apr 20
424B5
Prospectus supplement for primary offering
24 Apr 20
SC TO-T/A
Third party tender offer statement (amended)
20 Feb 20
SC TO-T/A
Third party tender offer statement (amended)
11 Feb 20
SC TO-T
Third party tender offer statement
22 Jan 20
SC TO-C
Information about tender offer
10 Jan 20
Proxies
PX14A6G
Letter to shareholders
27 Apr 20
DEFA14A
Additional proxy soliciting materials
15 Apr 20
DEFA14A
Additional proxy soliciting materials
7 Apr 20
PX14A6G
Letter to shareholders
24 Mar 20
PX14A6G
Letter to shareholders
24 Mar 20
PX14A6G
Letter to shareholders
23 Mar 20
DEFA14A
Additional proxy soliciting materials
20 Mar 20
DEFA14A
Additional proxy soliciting materials
20 Mar 20
DEF 14A
Definitive proxy
20 Mar 20
PRE 14A
Preliminary proxy
20 Feb 20
Other
SD
Conflict minerals disclosure
5 May 20
SD
Conflict minerals disclosure
9 May 19
SD
Conflict minerals disclosure
16 May 18
SD
Conflict minerals disclosure
30 May 17
NO ACT
No action letter
9 Mar 17
NO ACT
No action letter
23 Feb 17
NO ACT
No action letter
10 Feb 17
NO ACT
No action letter
13 Jan 17
UPLOAD
Letter from SEC
10 Aug 16
CORRESP
Correspondence with SEC
13 Jul 16
Ownership
4
ELI LILLY & Co / Melissa S Barnes ownership change
10 Sep 20
4
ELI LILLY & Co / Michael B Mason ownership change
2 Sep 20
4
ELI LILLY & Co / Stephen F Fry ownership change
18 Aug 20
4
ELI LILLY & Co / JACKSON P TAI ownership change
18 Aug 20
4
ELI LILLY & Co / JACKSON P TAI ownership change
21 Jul 20
4
ELI LILLY & Co / Alfonso G Zulueta ownership change
13 Jul 20
4
Change in insider ownership
10 Jul 20
4
Change in insider ownership
8 Jul 20
4
Change in insider ownership
7 Jul 20
4
ELI LILLY & Co / Leigh Ann Pusey ownership change
6 Jul 20
Patents
GRANT
Utility
Trigger assembly for automatic medication injection device
22 Sep 20
A trigger assembly for an automatic medication injection device.
GRANT
Utility
Azetidinyloxyphenylpyrrolidine compounds
22 Sep 20
Inventors: Gary G. Deng, Danwen Huang, Cynthia Darshini Jesudason, Joshua O. Odingo
GRANT
Utility
2,6-diamino pyridine compounds
22 Sep 20
Inventors: Timothy Barrett Durham
APP
Utility
BTK Inhibitor Compounds
17 Sep 20
The invention provides BTK Inhibitor compounds, pharmaceutically acceptable salts, pharmaceutical compositions thereof, and methods of using these compounds, salts, or compositions to treat autoimmune diseases such as Rheumatoid Arthritis.
GRANT
Utility
IgG bispecific antibodies and processes for preparation
15 Sep 20
The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.